 |
|
|
| |
Alisporivir (ALV) plus Peg-interferon/Ribavirin (P/R) Achieves High On-Treatment Undetectable HCV RNA Levels Among the Most Difficult to Treat HCV G1 Patients. Results of a Planned Treatment Week 24 Interim Analysis of a Randomized, Double Blind, Placebo Controlled Trial (FUNDAMENTAL study)
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
[1] G. Davis; [2] J. Kao; [3] A. Alberti; [4] W. Chuang; [5] R. Flisiak; [6] G. Mazzella; [7] A. Horban; [8] T. Goeser; [9] P. Calistru; [10] M. Buti; [11] A. Streinu-Cercel; [12] F. Tabak; [13] P. Desmond; [14] G. Horvath; [15] S. Pol; [16] G. Dusheiko; [17] Y. Gong; [18] R. Orsenigo; [18] C. Avila
[1] Baylor University Medical Center, Dallas TX, USA; [2] National Taiwan University Hospital, Taipei, Taiwan; [3] Azienda Ospedaliera Universita di Padova Univ.degli Studi, Padova, Italy; [4] Kaohsiung Medical University Hospital, Kaohsiung Taiwan; [5] Medical University, Bialystok, Poland; [6] Az. Osp. di Bologna Policl. S. Orsola-Malpighi, Bologna, Italy; [7] Warsa Medical University and Hosptial of Infectious Diseases, Warsaw, Poland; [8] Klinik fur Gastroenterologie und Hepatologie Universitatsklinik Koln, Germany; [9] Centrul de Diagnostic si Tratament Dr. Viktor Babes, Bucharest, Romania; [10] Liver Unit Hospital Vall D'Hebron and Ciber-ehd, Barcelona, Spain; [11] Matei Bals Institute of Infectious Diseases, Bucharest, Romania; [12] Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey; [13] St. Vincent's Hospital (Melb), Fitzroy, Australia; [14] Budai Hepatologiai Centrum, Budapest, Hungary; [15] Hopital Cochin, Paris, France; [16] Royal Free and University College Medical School, London, UK; [17] Shanghai Novartis Pharma Co. Ltd., Shanghai, China; [18] Novartis Pharma AG, Basel, Switzerland
|
| |
|
|
|
|
|
